News | March 24, 2010

Study of ICD Anti-Bacterial Envelope Begins

March 24, 2010 – Enrollment began this week in the CITADEL, which is the second of two large-scale, prospective, multicenter studies comparing implantable electrophysiology device infection rates. The study will look at patients with and without a new anti-bacterial envelope covering their devices.

CITADEL will enroll 2,300 patients at over 50 clinical study sites across the United States. Each patient is currently implanted with a pacemaker, implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device, which will be replaced with an ICD accompanied by AIGISRx. This patient population will be compared to a group of published control patients who have also undergone a pacemaker, ICD or CRT device replacement with an ICD without AIGISRx. The primary endpoints will be major ICD device-related infection and ICD device mechanical complication. Patients will be followed for 12 months, with pre-defined interim analyses at three and six months.

The first study, CENTURION, enrolled its first patient in January. CENTURION is a prospective, multicenter, monitored registry that will enroll 2,000 patients at more than 50 clinical study sites across the country. Each patient is currently implanted with a pacemaker, ICD or CRT device, which will be replaced with a CRT device accompanied by AIGISRx. This patient population will be compared to 2,000 case-matched controls that have also undergone a pacemaker, ICD or CRT device replacement with a CRT without AIGISRx. The primary endpoints will be major CRT device-related infection and CRT device mechanical complication. Patients will be followed for 12 months, with predefined interim analyses at three and six months.

AIGISRx is an anti-bacterial mesh envelope developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators. AIGISRx also securely holds a pacemaker or ICD in order to create a stable environment when implanted in the body.

“Device implanters are keenly aware of the risk of pocket infections, especially in patients with underlying health conditions,” Ibrahim Hanna, M.D., director of cardiac electrophysiology at Cardiology PC and Princeton Baptist Medical Center, Birmingham, Ala. “To date our ability to impact this issue has been limited. We are excited about the prospect of testing a simple, intuitive, and potentially highly effective approach to the problem. The TYRX antibacterial envelope is placed around the device and leads and left in the pocket allowing a cocktail of antibiotics to elute over seven days. We have enrolled our first patient in CITADEL and found the envelope very simple to use. It did not add any significant time or risk to the procedure and the whole process went very smoothly.

CENTURION and CITADEL are registered in the ClinicalTrials.gov registry of federally and privately supported clinical trials conducted in the United States and around the world (www.ClinicalTrials.gov).

For more information, please visit www.TYRX.com

Related Content

CHLA/USC Team Designs Novel Micropacemaker

Model of the human heart with microprocessor located in the pericardial sac and attached to the left ventricle. Graphic courtesy of Business Wire.

News | Pacemakers | June 29, 2018
Investigators at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) have...
Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block
News | Pacemakers | May 24, 2018
Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist...
Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System Detects Atrial Contractions, Restores AV Synchrony
News | Pacemakers | May 24, 2018
New clinical study results demonstrate that an investigational algorithm, utilizing the accelerometer signal in the...
The Boston Scientific Essentio MRI-safe pacemaker.

The Boston Scientific Essentio MRI-safe pacemaker. It is common for pacemaker patients to need magnetic resonance imaging (MRI), which has not previously been possible because the magnetic fields could damage older devices. All pacemaker vendors now have FDA-cleared MRI compatible pacemakers. 

Feature | Pacemakers | February 13, 2018 | Dave Fornell
There have been several advancements in pacemaker technologies over the past few years.
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

Mexican government reports conclude more than half of the population does not have access to social security or private insurance that covers a pacemaker implant, and 44 percent live in poverty. Recycling donated, explanted pacemakers offers a new option for these patients.

News | Pacemakers | November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers | June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Videos | Pacemakers | May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
micra leadless pacemaker
Feature | Pacemakers | May 16, 2017
May 16, 2017 - The preliminary results for the Medtronic Micra Transcatheter Pacing System (TPS) Post-Approval Regist
Videos | Pacemakers | May 16, 2017
This video, provided by Medtronic, demonstrates the implantation of Micra transcatheter pacing system (TPS).
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers | March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Overlay Init